Interview: Massimo Scaccabarozzi – President, Farmindustria, Italy
17.11.2015
Related Interviews
Italy / Guerbet's General Manager Italy & Iberia on Catching up from COVID's Diagnostic Backlog
Guerbet’s Alessandro Bocci – General Manager Italy & Iberia – describes the nearly 100-year-old company’s firm position in the field of contrast media for radiology and its plans for developing…
Italy / Lundbeck Italia's Managing Director on the Impact of COVID on Mental Health Care, the Danish Company's Italian Operation and Lundbeck’s Support of Independent Clinical Trials in the Country
Tiziana Mele, managing director of Lundbeck Italia, explains the impact of COVID on mental health care from the perspective of a company dedicated to brain health, outlines the Italian operation…
Italy/ Dr Nicola Normanno, Director of the Translational Research Department at Istituto Nazionale Tumori IRCCS Fondazione G. Pascale on Italy’s Progress with Next-Generation Sequencing (NGS)
Dr Nicola Normanno, the Director of the Translational Research Department of one of Italy’s national cancer institutes, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and president of the Italian Cancer…
Algeria / Pharma & Healthcare: 5 Things to Know
With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the…
Digital Transformation / 3 Insights from UCB CEO Jean-Christophe Tellier
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Germany / Bayer's Latest Woes; New EUR 2 bln Lilly Plant; Boehringer Ingelheim's T3 Pharma Acquisition
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
